PRT3645
Advanced or metastatic solid tumors
Key Facts
About Prelude Therapeutics
Prelude Therapeutics is dedicated to discovering and developing next-generation cancer treatments by targeting validated biological pathways with novel mechanisms. The company leverages its integrated discovery and development platform to advance a pipeline of small molecule candidates designed to address significant unmet needs in oncology. Its most advanced programs target SMARCA2/BRM and CDK9, with multiple candidates in clinical development. As a public company, Prelude is focused on generating clinical proof-of-concept data to validate its approach and create value for patients and shareholders.
View full company profileTherapeutic Areas
Other Advanced or metastatic solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| CHECKvacc (CF33-hNIS-antiPDL1) | Imugene | Phase 1 |
| VAXINIA (CF33-hNIS) | Imugene | Phase 1 |
| WTX-124 | Werewolf Therapeutics | Phase 1 |